Prostacyclin Synthase and Arachidonate 5-Lipoxygenase Polymorphisms and Risk of Colorectal Polyps
暂无分享,去创建一个
[1] S. Dey,et al. A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. , 2002, Endocrinology.
[2] V. Ullrich,et al. Molecular cloning and expression of human prostacyclin synthase. , 1994, Biochemical and biophysical research communications.
[3] E. Silverman,et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. , 1997, The Journal of clinical investigation.
[4] O. Rådmark. Arachidonate 5-lipoxygenase. , 2002, Journal of lipid mediators and cell signalling.
[5] Sakamoto,et al. Effect of shear stress and a stable prostaglandin I2 analogue on adhesive interactions of colon cancer cells and endothelial cells , 1999, Clinical and experimental immunology.
[6] M. Schirner,et al. Inhibition of metastasis by cicaprost in rats with established SMT2A mammary carcinoma growth. , 1997, Cancer detection and prevention.
[7] A. Zauber,et al. The National Polyp Study , 1990 .
[8] S. Humphries,et al. Common Promoter Variant in Cyclooxygenase-2 Represses Gene Expression: Evidence of Role in Acute-Phase Inflammatory Response , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[9] G. Thomas,et al. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. , 1994, Gut.
[10] S. Lippman,et al. Lipoxygenase modulation to reverse carcinogenesis. , 2001, Cancer research.
[11] B. Rigas,et al. Altered eicosanoid levels in human colon cancer. , 1993, The Journal of laboratory and clinical medicine.
[12] V. Moreno,et al. Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy , 2005, Oncogene.
[13] I. Sayers,et al. Promoter polymorphism in the 5‐lipoxygenase (ALOX5) and 5‐lipoxygenase‐activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[14] J. Vane,et al. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.
[15] T. Adrian,et al. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. , 2002, Molecular cancer therapeutics.
[16] Y. Miller,et al. Pulmonary Prostacyclin Synthase Overexpression Chemoprevents Tobacco Smoke Lung Carcinogenesis in Mice , 2004, Cancer Research.
[17] S. Paruchuri,et al. The leukotriene receptor CysLT1 and 5-lipoxygenase are upregulated in colon cancer. , 2003, Advances in experimental medicine and biology.
[18] T. Żebro,et al. Prostaglandins from tumours of human large bowel. , 1977, British Journal of Cancer.
[19] N. Bresolin,et al. A collection of 33 novel human mtDNA homoplasmic variants , 2002, Human mutation.
[20] W. Koh,et al. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: The Singapore Chinese Health Study , 2004, British Journal of Cancer.
[21] T. Nakayama,et al. Nonsense mutation of prostacyclin synthase gene in a family , 1997, The Lancet.
[22] T. Moody,et al. Five‐lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[23] C. Ulrich,et al. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[24] Y. Miller,et al. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. , 2002, Cancer research.
[25] K. Honn,et al. Prostacyclin: a potent antimetastatic agent. , 1981, Science.
[26] M. Romano,et al. Cyclooxygenase‐2 and 5‐lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] C. Ulrich,et al. TGFbeta1 polymorphism (L10P) and risk of colorectal adenomatous and hyperplastic polyps. , 2004, International journal of epidemiology.
[28] G. Beck,et al. A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.
[29] L. Ermert,et al. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] Henry J. Lin,et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[31] D. Rader,et al. COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice , 2004, Science.
[32] J. Potter,et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. , 2001, Cancer research.
[33] T. Ogihara,et al. Human prostacyclin synthase gene and hypertension : the Suita Study. , 1999, Circulation.
[34] M. Maemondo,et al. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. , 2002, Cancer research.
[35] H. Friess,et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. , 2002, The American journal of pathology.
[36] H. Sheng,et al. Cyclooxygenase-2 induction and transforming growth factor beta growth inhibition in rat intestinal epithelial cells. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[37] E. Giovannucci. The prevention of colorectal cancer by aspirin use. , 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[38] Jeannette Bigler,et al. Cyclooxygenase 1 (COX1) polymorphisms in African‐American and caucasian populations , 2002, Human mutation.
[39] T. Nakayama,et al. Association of 5' upstream promoter region of prostacyclin synthase gene variant with cerebral infarction. , 2000, American journal of hypertension.
[40] M. Vos,et al. 5‐lipoxygenase inhibitors reduce PC‐3 cell proliferation and initiate nonnecrotic cell death , 1998, The Prostate.
[41] J. Vane. Prostacyclin: a hormone with a therapeutic potential. The Sir Henry Dale Lecture for 1981. , 1982, The Journal of endocrinology.
[42] C. Ulrich,et al. Polymorphisms in PTGS1 (=COX-1) and risk of colorectal polyps. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[43] W. Wu,et al. Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. , 2004, Toxicology.
[44] J. Drazen,et al. Genetic variations in the 5-lipoxygenase core promoter. Description and functional implications. , 2000, American journal of respiratory and critical care medicine.
[45] T. Louis,et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[46] A. Zauber,et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. , 1990, Gastroenterology.
[47] John D Potter,et al. Risk factors for hyperplastic and adenomatous polyps: evidence for malignant potential? , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[48] S. Chanock,et al. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. , 2004, Carcinogenesis.
[49] J. Ajani,et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. , 2005, Carcinogenesis.
[50] M. Taketo. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). , 1998, Journal of the National Cancer Institute.
[51] C. Ulrich,et al. PTGS2 (COX-2) −765G > C Promoter Variant Reduces Risk of Colorectal Adenoma among Nonusers of Nonsteroidal Anti-inflammatory Drugs , 2005, Cancer Epidemiology Biomarkers & Prevention.
[52] S. Martinotti,et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. , 2004, JAMA.
[53] Tom S. Price,et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. , 2006, Gastroenterology.
[54] Susan Halabi,et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.
[55] J. Lo-Guidice,et al. Characterization of new mutations in the coding sequence and 5'-untranslated region of the human prostacyclin synthase gene (CYP8A1) , 2001, Human Genetics.
[56] C. Funk,et al. Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.
[57] J. Chang-Claude,et al. A Transforming Growth Factorβ1 Signal Peptide Variant Increases Secretion in Vitro and Is Associated with Increased Incidence of Invasive Breast Cancer , 2003 .